Healthcare Industry News: UCB
News Release - March 24, 2016
Ajanta Pharma Announces the Launch of Levetiracetam TabletsBRIDGEWATER, N.J., March 24, 2016 -- (Healthcare Sales & Marketing Network) -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Levetiracetam Immediate-Release Tablets (250mg, 500mg, 750mg, 1000mg), a bioequivalent generic version of Keppraź in the US market.
Ajanta Pharma's launch of Levetiracetam Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (FDA) has granted Ajanta Pharma eight ANDA final approvals and two tentative approvals. An additional 16 ANDAs are pending approval from the FDA.
About Ajanta Pharma
Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing quality, pharmaceuticals across 35 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
 Keppra is a registered trademark of UCB Pharma
Source: Ajanta Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.